237 related articles for article (PubMed ID: 28116452)
1. Understanding therapeutic targets in thrombotic thrombocytopenic purpura.
Joly BS; Vanhoorelbeke K; Veyradier A
Intensive Care Med; 2017 Sep; 43(9):1398-1400. PubMed ID: 28116452
[No Abstract] [Full Text] [Related]
2. Therapeutic plasma exchange in thrombotic thrombocytopenic purpura.
Picod A; Provôt F; Coppo P
Presse Med; 2019 Nov; 48(11 Pt 2):319-327. PubMed ID: 31759790
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic thrombocytopenic purpura: The role of ADAMTS13.
Rogers HJ; Allen C; Lichtin AE
Cleve Clin J Med; 2016 Aug; 83(8):597-603. PubMed ID: 27505881
[TBL] [Abstract][Full Text] [Related]
4. Thrombotic Thrombocytopenic Purpura: Beyond Empiricism and Plasma Exchange.
Tsai HM
Am J Med; 2019 Sep; 132(9):1032-1037. PubMed ID: 30928346
[TBL] [Abstract][Full Text] [Related]
5. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM
Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285
[TBL] [Abstract][Full Text] [Related]
6. Management of thrombotic thrombocytopenic purpura.
Coppo P;
Transfus Clin Biol; 2017 Sep; 24(3):148-153. PubMed ID: 28645643
[TBL] [Abstract][Full Text] [Related]
7. Transfusion of Platelets Loaded With Recombinant ADAMTS13 (A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13) Is Efficacious for Inhibiting Arterial Thrombosis Associated With Thrombotic Thrombocytopenic Purpura.
Abdelgawwad MS; Cao W; Zheng L; Kocher NK; Williams LA; Zheng XL
Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2731-2743. PubMed ID: 30354235
[TBL] [Abstract][Full Text] [Related]
8. Recombinant ADAMTS13 for Immune Thrombotic Thrombocytopenic Purpura.
Bendapudi PK; Foy BH; Mueller SB; Liu J; Feingold LM; Burke KE; Cruz W; Chen MY; Lau ES; Goldberg RL; Tatake I; Wilkinson SC; Carney BJ; Stone JR; Park D; Avelino AR; Hassan S; Andrzejewski C; Ruby KN; Friedman KD; Brunker PAR; Leaf RK; Higgins J; Dzik WH; Stefely JA; Makar RS
N Engl J Med; 2024 May; 390(18):1690-1698. PubMed ID: 38718359
[TBL] [Abstract][Full Text] [Related]
9. Emerging roles of adjunct therapies in acquired thrombotic thrombocytopenia purpura.
Racine-Brzostek SE; Shi PA
Transfusion; 2019 Aug; 59(8):2496-2498. PubMed ID: 31283011
[TBL] [Abstract][Full Text] [Related]
10. Current and Future Perspectives on ADAMTS13 and Thrombotic Thrombocytopenic Purpura.
Roose E; Joly BS
Hamostaseologie; 2020 Aug; 40(3):322-336. PubMed ID: 32726827
[TBL] [Abstract][Full Text] [Related]
11. A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura.
Gómez-Seguí I; Fernández-Zarzoso M; de la Rubia J
Expert Rev Hematol; 2020 Nov; 13(11):1153-1164. PubMed ID: 32876503
[No Abstract] [Full Text] [Related]
12. Rainbow of hemolysis associated with acquired thrombotic thrombocytopenic purpura.
Raval JS; Mazepa MA; Kim-Shapiro DB; Basu S; Kasthuri RS; Whinna HC; Park YA
J Clin Apher; 2017 Aug; 32(4):274-275. PubMed ID: 27530891
[TBL] [Abstract][Full Text] [Related]
13. Predictive Value of Schistocytes in Recurrence of Acquired Thrombotic Thrombocytopenic Purpura With Severe ADAMTS13 Deficiency at Discontinuation of Daily Therapeutic Plasma Exchange.
Peedin AR; Park YA; Mazepa MA; Rollins-Raval MA; Brecher ME; Raval JS
Ther Apher Dial; 2018 Dec; 22(6):662-665. PubMed ID: 30178615
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of diagnosis, treatment, and management for immune thrombotic thrombocytopenic purpura: Are we still peering through the looking glass?
Raval JS; Rollins-Raval MA; Mazepa MA; Park YA
J Clin Apher; 2020 Jun; 35(3):236-237. PubMed ID: 32449953
[No Abstract] [Full Text] [Related]
15. Outcome of Thrombotic Thrombocytopenic Purpura Patients: A Single-Center Experience.
Çeneli Ö; Yılmaz S; Karaselek MA; Çamlı K
Turk J Haematol; 2019 Aug; 36(3):214-215. PubMed ID: 30905143
[No Abstract] [Full Text] [Related]
16. Inherited thrombotic thrombocytopenic purpura mimicking immune thrombocytopenic purpura during pregnancy: a case report.
Romão de Souza V; Beatriz Cavalcante de Oliveira A; Maria Vanderlei A; Queiroz da Mota Silveira Aroucha A; Pontes Duarte B; Nunes Machado A; Netto Chaer L; Wanderley de Barros Correia C; da Conceição de Barros Correia M; Freire Hazin Costa M
J Med Case Rep; 2018 Jan; 12(1):15. PubMed ID: 29357939
[TBL] [Abstract][Full Text] [Related]
17. ADAMTS13-specific circulating immune complexes as potential predictors of relapse in patients with acquired thrombotic thrombocytopenic purpura.
Mancini I; Ferrari B; Valsecchi C; Pontiggia S; Fornili M; Biganzoli E; Peyvandi F;
Eur J Intern Med; 2017 Apr; 39():79-83. PubMed ID: 27887777
[TBL] [Abstract][Full Text] [Related]
18. Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura.
George JN
Am J Hematol; 2012 May; 87 Suppl 1():S88-91. PubMed ID: 22407740
[TBL] [Abstract][Full Text] [Related]
19. Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease.
Lämmle B; Kremer Hovinga JA; George JN
Haematologica; 2008 Feb; 93(2):172-7. PubMed ID: 18245649
[No Abstract] [Full Text] [Related]
20. Current management of thrombotic thrombocytopenic purpura.
Kremer Hovinga JA; Meyer SC
Curr Opin Hematol; 2008 Sep; 15(5):445-50. PubMed ID: 18695366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
